Achieve Life Sciences Adds Marketing Chief Ahead of Key NDA Resubmission
Event summary
- Achieve Life Sciences appoints Kaitlyn Tuson as SVP of Marketing and Communications effective October 7, 2026.
- Tuson brings 15 years of healthcare marketing experience, including six pharma launches, three of which were blockbuster therapies.
- Appointment follows a $354 million financing and other executive hires in 2026 as Achieve prepares for potential cytisinicline commercialization.
- Company plans NDA resubmission for cytisinicline, a treatment for nicotine dependence, supported by two Phase 3 studies.
The big picture
Achieve's appointment of Tuson signals a strategic push toward commercialization as it prepares for cytisinicline's potential market entry. The move comes amid a broader industry shift toward innovative smoking cessation treatments, with the FDA's Breakthrough Therapy designation highlighting the unmet need in nicotine e-cigarette cessation. Achieve's ability to execute its commercialization plans will be critical in capturing market share in a space dominated by well-established therapies.
What we're watching
- Regulatory Timing
- Whether Achieve can secure FDA approval for cytisinicline on its anticipated timeline following NDA resubmission.
- Market Penetration
- How effectively Tuson can position cytisinicline in a market dominated by established smoking cessation aids.
- Commercial Readiness
- The pace at which Achieve can scale its commercial operations to meet potential demand for cytisinicline.
Related topics